Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
Autor: | Michael A Ueberall, Ute Essner, Gerhard Hh Mueller-Schwefe |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
add-on treatment THC:CBD spray 03 medical and health sciences 0302 clinical medicine Refractory 030202 anesthesiology German pain e-Registry Internal medicine medicine Journal of Pain Research Original Research neuropathic pain biology business.industry Chronic pain severe chronic pain medicine.disease biology.organism_classification retrospective analysis Dysgeusia Anesthesiology and Pain Medicine Nociception Tolerability Neuropathic pain Cannabis medicine.symptom business Cannabidiol 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Journal of Pain Research |
ISSN: | 1178-7090 |
DOI: | 10.2147/jpr.s192174 |
Popis: | Michael A Ueberall,1 Ute Essner,2 Gerhard HH Mueller-Schwefe31Institute of Neurological Sciences, 90411 Nuernberg, Germany; 2O.Meany Consultancy, 22339 Hamburg, Germany; 3Interdisciplinary Centre for Pain and Palliative Care Medicine, 73033 Goeppingen, GermanyObjective: To evaluate effectiveness, tolerability and safety of an oromucosal spray containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as add-on treatment in patients with severe chronic pain (SCP).Methods: Exploratory analysis of anonymized 12-week routine/open-label data provided by the German Pain e-Registry (GPR) on adult SCP patients treated with THC:CBD oromucosal spray in 2017.Results: Among those 30.228 cases documented in the GPR in 2017, 800 (2.6%; 57% female, mean ± SD age: 46.3±9.7 years) received a treatment with THC:CBD. All patients fulfilled the legislative preconditions for a treatment with cannabis as medicine as defined by the German Act Amending Narcotics and Other Regulations. THC:CBD-treatment was followed by an aggregated nine-factor symptom relief (ASR-9) improvement at end of week 12 vs baseline of 39.0±26.5% (95%-CI: 36.9–41.1, median: 42, range −41 to 85). A full ASR-9 response (ie, a 50%-improvement in all 9 factors) was found for 123 patients (15.4%), while 488 patients (56.0%) presented with an ≥50% improvement in at least 5 of 9 ASR factors. With a 54.9±17.2% (median: 56%, range: −6 to 85) improvement was significantly superior in the neuropathic pain subgroup (n=497, 62.1%) vs those with mixed (n=249, 31.1%; ASR-9: 18.2±12.0, median: 19, range: −12 to 42%) or nociceptive pain (n=54, 6.8%; ASR-9: −11.9±10.5, median: −11, range: −41% to 12%; p |
Databáze: | OpenAIRE |
Externí odkaz: |